4D Path
Updated: January 28, 2026
Founder Rodrigo Navarro
Country: USA | Funding: $18.8M (+)
Website: https://www.4dpath.com/
4D Path develops QPOR platform, designed to directly measure and quantify cell cycle abnormalities and tumor microenvironment dynamics to predict patient response to therapy. It uses hematoxylin and eosin (H&E)-stained biopsy images to instantly uncover hidden data, enabling biomarker profiling and stratification. While the company initially focuses on breast cancer, it is actively developing products for ovarian cancer, cervical cytology, skin cancer, and, more broadly, immunotherapy for various cancer types.
Website: https://www.4dpath.com/
4D Path develops QPOR platform, designed to directly measure and quantify cell cycle abnormalities and tumor microenvironment dynamics to predict patient response to therapy. It uses hematoxylin and eosin (H&E)-stained biopsy images to instantly uncover hidden data, enabling biomarker profiling and stratification. While the company initially focuses on breast cancer, it is actively developing products for ovarian cancer, cervical cytology, skin cancer, and, more broadly, immunotherapy for various cancer types.
